Today we're going to take a look at the well-established Synopsys, Inc. ( NASDAQ:SNPS ). The company's stock received ...

Synopsys SNPS has outperformed the market over the past 20 years by 10.25% on an annualized basis producing an average annual ...

Synopsys (SNPS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth ...

He says ‘despite five SNP MSPs from the region taking hefty ministerial salaries, the Highlands keeps missing out’.

Shares of Synopsys Inc. SNPS inched 0.21% higher to $506.83 Tuesday, on what proved to be an all-around positive trading ...

Synopsys Inc (SNPS) stock saw a modest uptick, ending the day at $514.12 which represents a slight increase of $18.17 or 3.66% from the prior close of $495.95. The stock opened at $517.18 and touched ...

Below is Validea's guru fundamental report for SYNOPSYS INC (SNPS). Of the 22 guru strategies we follow, SNPS rates highest using our P/B Growth Investor model based on the published strategy of ...

It has been about a month since the last earnings report for Synopsys (SNPS). Shares have lost about 6.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Shares of Synopsys Inc. SNPS shed 0.17% to $505.79 Monday, on what proved to be an all-around favorable trading session for ...

While smoking rates are declining in other parts of the world, data shows that the African region and other Low-Income ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.